Triple-negative Breast Cancer
📧 Sign up to get email alerts when something new happens for Triple-negative Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-09-30Clinical Trial Update: Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations [Phase 2]
A Phase 2 trial evaluating nab-paclitaxel in combination with alpelisib for anthracycline-refractory triple-negative breast cancer with PIK3…
-
CLINICAL_TRIALS research · 2025-09-29Clinical Trial Update: A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients [Phase 1]
Phase I trial evaluating Niraparib given concurrently with postoperative radiotherapy in patients with triple-negative breast cancer.
-
CLINICAL_TRIALS research · 2025-09-26Clinical Trial Update: A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer or Other Solid Tumors [Phase 1]
This is a Phase 1 clinical trial update for BL-M02D1 in patients with locally advanced or metastatic triple-negative breast cancer and other…
-
CLINICAL_TRIALS research · 2025-09-25Clinical Trial Update: Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases [Phase 2]
Phase II trial assessing Dato-DXd in triple-negative breast cancer patients with newly diagnosed or progressing brain metastases is currentl…
-
CLINICAL_TRIALS research · 2025-09-24Clinical Trial Update: A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors [Phase 1, Phase 2]
Clinical trial update on Invikafusp alfa in combination with sacituzumab govitecan in adults with advanced solid tumors, including triple-ne…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-09-23Clinical Trial Update: The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC [Phase 1]
Phase 1 study evaluating whether bexarotene can increase chemotherapy sensitivity in metastatic triple-negative breast cancer has completed …
-
CLINICAL_TRIALS research · 2025-09-23Clinical Trial Update: The Neoadjuvant Treatment of Early High-risk Triple Negative Breast Cancer With HRD Positive With Iparomlimab and Tuvonralimab Combined With Olaparib and Paclitaxel [NA]
Clinical trial update describing a neoadjuvant regimen for early high-risk triple-negative breast cancer in HRD-positive tumors using a comb…
-
CLINICAL_TRIALS research · 2025-09-23Clinical Trial Update: A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer [Phase 3]
A Phase III clinical trial evaluating ESG401 for unresectable recurrent or metastatic triple-negative breast cancer is currently recruiting.
-
CLINICAL_TRIALS research · 2025-09-23Clinical Trial Update: PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC [Phase 2]
A phase 2 clinical trial at Johns Hopkins is evaluating PET-guided, response-adapted neoadjuvant therapy for triple-negative breast cancer a…
-
CLINICAL_TRIALS research · 2025-09-19Clinical Trial Update: Communicating With Patients on Cancer Resistance to Treatment: the Development of a Communication Tool. (HECTOR) [NA]
The document reports the completion of a study to develop a patient communication tool (HECTOR) for discussing cancer treatment resistance, …
-
CLINICAL_TRIALS research · 2025-09-18Clinical Trial Update: Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer [Phase 3]
A Phase 3 trial compares sacituzumab govitecan-hziy plus pembrolizumab against physician's choice plus pembrolizumab in previously untreated…
-
CLINICAL_TRIALS trial_result · 2025-09-17Clinical Trial Update: NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer [Phase 3]
Phase 3 trial evaluating neoadjuvant Sacituzumab Govitecan plus Pembrolizumab versus standard-of-care chemotherapy in clinical stage II-III …
-
CLINICAL_TRIALS research · 2025-09-17Clinical Trial Update: Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer [Phase 1, Phase 2]
Scancell's Modi-1 Moditope is being studied in Phase 1/2 trials across several cancers, including triple-negative breast cancer, renal cell …
-
CLINICAL_TRIALS research · 2025-09-15Clinical Trial Update: Omission of Local Therapies in Women Patients With HER2-positive or Triple-negative Breast Cancer [Phase 2]
This document provides a Phase 2 clinical trial update on omitting local therapies in women with HER2-positive or triple-negative breast can…
-
CLINICAL_TRIALS trial_result · 2025-09-15Clinical Trial Update: Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies [Phase 1]
Ongoing Phase 1 safety/efficacy trial of CID-078 in patients with advanced/metastatic solid tumors; study is currently recruiting.
-
CLINICAL_TRIALS research · 2025-09-12Clinical Trial Update: NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC [Phase 3]
NordicTrip is a Phase 3 translational study evaluating preoperative chemotherapy for triple-negative breast cancer; the trial is currently a…
-
CLINICAL_TRIALS research · 2025-09-11Clinical Trial Update: Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer [Phase 2]
This Phase 2 clinical trial compares nab-paclitaxel plus carboplatin versus nab-paclitaxel plus capecitabine in advanced triple-negative bre…
-
CLINICAL_TRIALS research · 2025-09-11Clinical Trial Update: SC-101 in Subjects With Advanced NECTIN4-Amplified Cancers [Phase 2]
A Phase 2 clinical trial update for SC-101 in nectin-4 amplified cancers, including triple-negative breast cancer and hormone receptor-posit…
-
CLINICAL_TRIALS research · 2025-09-11Clinical Trial Update: Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer [Phase 2]
A Phase 2 neoadjuvant breast cancer trial compares nab-paclitaxel plus carboplatin versus nab-paclitaxel plus epirubicin; the study is curre…
-
CLINICAL_TRIALS trial_result · 2025-09-09Clinical Trial Update: Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBC [Phase 1, Phase 2]
A Phase 1/2 study evaluating leronlimab (PRO 140) in combination with carboplatin for CCR5-positive metastatic triple-negative breast cancer…
-
CLINICAL_TRIALS research · 2025-09-09Clinical Trial Update: Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer [Phase 1, Phase 2]
A Phase 1/2 trial evaluating camrelizumab with pirfenidone and chemotherapy for advanced triple-negative breast cancer; the study status is …
-
CLINICAL_TRIALS research · 2025-09-09Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression [Phase 1, Phase 2]
A2 Biotherapeutics is evaluating A2B395, an allogeneic logic-gated CAR T therapy, in Phase 1/2 trials for solid tumors expressing EGFR and l…
-
CLINICAL_TRIALS research · 2025-09-09Clinical Trial Update: Grouping Immune-modulation With Cryoablation (LOGIC) for Breast Cancers [Phase 1, Phase 2]
This clinical trial update describes the LOGIC study testing immune-modulation combined with cryoablation for triple-negative breast cancer,…
-
CLINICAL_TRIALS research · 2025-09-08Clinical Trial Update: A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC [Phase 2]
Phase 2 trial update comparing Sacituzumab Govitecan plus Toripalimab versus Toripalimab plus Nab-Paclitaxel in PD-L1 positive advanced trip…
-
CLINICAL_TRIALS trial_result · 2025-09-05Clinical Trial Update: START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer [Phase 1]
Phase 1 trial update of PeptiCRAd-1 reports safety signals and anti-tumor activity across multiple cancers; trial status is ACTIVE_NOT_RECRU…